AB-FUBINACA

AB-FUBINACA is a powerful synthetic cannabinoid that has significant research applications. This comprehensive guide will give you all the information that you need about AB FUBINACA. We’ll cover its chemical properties, development, effects, uses and dosage.

Development and Background

AB-FUBINACA, a synthetic cannabinoid, was developed by Pfizer as a possible analgesic in 2009. AB-FUBINACA, although not approved for medical or human use, has drawn considerable interest from researchers because of its unique pharmacological characteristics and potential therapeutic applications.

CAS Number and Chemical name

The CAS number for AB FUBINACA is 1185282-01-2. This number serves as a unique identifier in scientific databases. The IUPAC (International Union of Pure and Applied Chemistry) name for AB-FUBINACA is N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide. This name provides researchers with a standard reference and describes the chemical structure of the compound.

Molecular Formula

The molecular formula of AB-FUBINACA is C20H21FN4O2, which means that it contains 20 carbon atoms and 21 hydrogen atoms. It also contains one fluorine atom as well as four nitrogen atoms and two oxygen atoms. It has a molecular mass of 368.42 grams/mol.

Shape and color of the compound

AB-FUBINACA is typically a powdery white or off-white color. Its crystalline structure makes it easy to work with and handle during research. Store AB-FUBINACA away from heat, direct sunlight, and in a dry, cool place to maintain its integrity.

Uses and effects of AB FUBINACA

AB-FUBINACA is not approved for human consumption, nor medical use. However, it has been used in scientific research as a potent agonist of the CB1 cannabinoid receptors. These receptors are essential in many physiological processes such as the regulation of pain, immune system functions, and mood regulation. Researchers are studying AB-FUBINACA in order to better understand the endocannabinoid systems and the therapeutic benefits of synthetic cannabis.

AB-FUBINACA has a high affinity and selectivity towards the CB1 (brain) receptor. The compound mimics the effects of cannabinoids such as THC. These effects can include feelings of euphoria and relaxation, altered perceptions, and an increased appetite. Due to its potency, AB FUBINACA may also have more intense side effects.

Dosage and precautions

AB-FUBINACA, a research chemical that has not been approved by the FDA for human consumption is to be handled with extreme caution. Researchers who work with AB-FUBINACA must adhere to strict safety protocol, including wearing personal protective equipment (PPE) and implementing proper ventilation.

In vitro and in vivo, the dose of AB FUBINACA must be determined carefully based on study objectives and conditions. When designing experiments, researchers must also consider the compound’s potency as well as its potential for adverse side effects.

AB-FUBINACA has significant research potential. Researchers can use its unique chemical structure, pharmacological profiles, and ease-of-handling to study the effects of cannabis.

Synthetic cannabinoids and their potential therapeutic uses. AB-FUBINACA, despite its potential scientific breakthroughs is not intended for therapeutic or human use.

Safety and Legal Considerations

AB-FUBINACA and other synthetic cannabinoids are subject to varying levels of legal restrictions in different countries. Researchers are required to be familiar with and adhere to local, national and international laws that govern the possession, usage and distribution of these substances. Some jurisdictions may require specific licenses or permits to work with synthetic cannabis like AB-FUBINACA.

Researchers must also prioritize safety when using AB-FUBINACA. It is important to use extreme caution when handling the compound due to its potency and the potential for adverse reactions. Researchers must always take appropriate safety measures such as using personal protective equipment, adequate ventilation and adhering to laboratory protocols.

The conclusion of the article is:

AB-FUBINACA, a promising cannabinoid synthetic compound with potential for advanced applications in research, is a promising product. Researchers can use its unique chemical structure, potency and affinity for CB1-CB2-receptors to study the endocannabinoid systems and potential therapeutic uses for synthetic cannabinoids. Researchers can unlock the mysteries surrounding AB-FUBINACA by adhering to strict safety protocols.